Bence Kővári Selected Research

Syntaxin 1

4/2021	The panel of syntaxin 1 and insulinoma-associated protein 1 outperforms classic neuroendocrine markers in pulmonary neuroendocrine neoplasms.
2/2020	Syntaxin 1: A Novel Robust Immunophenotypic Marker of Neuroendocrine Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bence Kővári Research Topics

Disease

10	Neoplasms (Cancer) 09/2021 - 09/2014
7	Breast Neoplasms (Breast Cancer) 01/2021 - 04/2014
6	Carcinoma (Carcinomatosis) 04/2021 - 09/2014
3	Heart Diseases (Heart Disease) 11/2021 - 10/2016
3	Fibrosis (Cirrhosis) 11/2021 - 01/2019
3	Heart Failure 11/2021 - 01/2019
2	Polyps 04/2022 - 01/2021
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 11/2021
2	Insulinoma 04/2021 - 01/2021
2	Hypertrophy 01/2019 - 01/2019
1	Hypercholesterolemia 01/2022
1	Insulin Resistance 01/2022
1	Obesity 01/2022
1	Gallbladder Neoplasms (Gallbladder Cancer) 09/2021
1	Carcinoid Tumor (Carcinoid) 04/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2021
1	Adenocarcinoma 01/2021
1	Infarction (Infarctions) 01/2021
1	Chronic Renal Insufficiency 01/2021
1	Inflammation (Inflammations) 01/2021
1	Colitis 12/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2020
1	Papillary Carcinoma 06/2018
1	Heart Injuries 10/2016
1	Cytomegalovirus Infections (Inclusion Disease) 08/2016
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2015

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2021
4	AntibodiesIBA 01/2017 - 04/2014
2	Losartan (Cozaar)FDA LinkGeneric 11/2021 - 01/2021
2	Angiotensin Receptor AntagonistsIBA 11/2021 - 01/2021
2	Syntaxin 1IBA 04/2021 - 02/2020
2	Chromogranin AIBA 04/2021 - 01/2021
2	SynaptophysinIBA 04/2021 - 01/2021
2	salicylhydroxamic acid (SHAM)IBA 01/2021 - 01/2019
2	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 01/2019 - 01/2019
2	AMP-Activated Protein KinasesIBA 01/2019 - 01/2019
2	CalcineurinIBA 01/2019 - 01/2019
2	Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA 01/2017 - 09/2014
1	MucinsIBA 04/2022
1	oxidized low density lipoproteinIBA 01/2022
1	Apolipoprotein B-100 (Apo B 100)IBA 01/2022
1	HDL LipoproteinsIBA 01/2022
1	HDL CholesterolIBA 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022
1	Transforming Growth Factor beta (TGF-beta)IBA 11/2021
1	Chymases (Chymase)IBA 11/2021
1	Connective Tissue Growth FactorIBA 11/2021
1	Bile Pigments (Bilin)IBA 09/2021
1	4-O-carboxymethylascochlorinIBA 01/2021
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	Adenosine Triphosphatases (ATPase)IBA 01/2021
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2021
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021
1	mirabegronIBA 01/2021
1	phospholambanIBA 01/2021
1	Angiotensin IIIBA 01/2021
1	teriflunomideIBA 12/2020
1	HSP40 Heat-Shock ProteinsIBA 01/2019
1	Sirtuin 1IBA 01/2019
1	MEF2 Transcription FactorsIBA 01/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	TensinsIBA 01/2019
1	erucylphosphocholineIBA 06/2018
1	Estrogen ReceptorsIBA 01/2018
1	Formaldehyde (Formol)FDA Link 01/2017
1	ParaffinIBA 01/2017
1	Protective AgentsIBA 10/2016
1	Antiviral Agents (Antivirals)IBA 08/2016
1	Keratin-5 (Keratin 5)IBA 09/2015
1	Phenobarbital (Luminal)FDA Link 01/2015
1	somatotropin releasing hormone receptorIBA 09/2014
1	arginyl- threonyl- prolyl- prolyl- prolyl- seryl- glycine (SP 6)IBA 04/2014

Therapy/Procedure

3	Radiotherapy 11/2021 - 10/2016
2	Neoadjuvant Therapy 01/2018 - 01/2015
2	Therapeutics 08/2016 - 01/2015
1	Nephrectomy 01/2021
1	Lymph Node Excision (Lymph Node Dissection) 01/2018
1	Drug Therapy (Chemotherapy) 08/2016
1	Stem Cell Transplantation 08/2016